HCC - Hepatocellular Carcinoma Clinical Trials

76 clinical trials for HCC - Hepatocellular Carcinoma across international registries, including 33 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence — RECRUITING · PHASE3
• Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma — RECRUITING
• A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC — RECRUITING · PHASE2
• A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma — RECRUITING
• OE MRI to Predict Treatment Response After TACE in HCC Patients — RECRUITING · NA
• Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma — RECRUITING
• Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma — RECRUITING · PHASE2
• Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma — RECRUITING
• A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• Needle-based Percutaneous Ablation of Liver Tumors. — RECRUITING · NA
• Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma — RECRUITING · PHASE2
• Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study — RECRUITING · NA
• The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD — RECRUITING · PHASE2
• Study of GV20-0251 in Participants With Solid Tumor Malignancies — RECRUITING · PHASE1
• ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC — RECRUITING · PHASE2
• A Study of GV20-0251 in Advanced or Refractory Solid Tumors — RECRUITING · PHASE1
• [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling. — RECRUITING · NA
• Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC — RECRUITING · PHASE2
• The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study — RECRUITING
• Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC — RECRUITING · PHASE4
• Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) — RECRUITING · PHASE2
• Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals — RECRUITING
• Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma — RECRUITING
• Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC — RECRUITING · PHASE2
• ctDNA Monitoring in Patients With HCC and mCRC — RECRUITING · NA
• FGF19 Overexpression Combination Unified Study in HCC-19 — RECRUITING · PHASE2
• A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. — RECRUITING · PHASE1
• Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy — RECRUITING · PHASE2
• Sarcopenia and Systemic Therapy in HCC — RECRUITING
• Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation? — RECRUITING
• Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study — RECRUITING
• Mts105 for Advanced Hepatocellular Carcinoma — RECRUITING · PHASE1
• PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies — RECRUITING
• Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma — NOT_YET_RECRUITING · PHASE1
• Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome — NOT_YET_RECRUITING · PHASE2
• A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma — NOT_YET_RECRUITING · PHASE2
• SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma — NOT_YET_RECRUITING · PHASE4
• Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy — NOT_YET_RECRUITING · PHASE2
• Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI — ACTIVE_NOT_RECRUITING · PHASE2
• Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes — NOT_YET_RECRUITING · PHASE2
• Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma — ACTIVE_NOT_RECRUITING
• A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors — NOT_YET_RECRUITING · NA
• Defining the Ablative Dose for Y-90 TARE — NOT_YET_RECRUITING · PHASE2
• The DoHAICs Study Expansion Phase — NOT_YET_RECRUITING · PHASE2
• Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer — SUSPENDED · PHASE1
• Social Determinants of Health HCC Trial — NOT_YET_RECRUITING · NA
• Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure — ACTIVE_NOT_RECRUITING · PHASE2
• A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma — NOT_YET_RECRUITING · NA
• Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin — NOT_YET_RECRUITING · PHASE2
• A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk — NOT_YET_RECRUITING · PHASE2

Refine this search